STAMPEDE Combined Analysis of ADT Plus Abiraterone Acetate + Prednisolone ± Enzalutamide vs ADT Alone in High-Risk Nonmetastatic Prostate Cancer

September 16-21, 2021; Virtual
In this combined analysis from the ongoing STAMPEDE platform trial, 2 years of abiraterone acetate plus prednisolone added to ADT was associated with a significant improvement in metastasis-free survival and OS in patients with high-risk nonmetastatic prostate cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 250 KB
Released: September 30, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

On-demand webcast of a live webinar on the urologist’s role in testing and using PARP inhibitors for prostate cancer, from Clinical Care Options (CCO)

person default Stephen Freedland, MD Rana R. McKay, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: November 30, 2022 Expired: November 29, 2023

On-demand webcast: Brenda Martone, MSN, ANP-BC, AOCNP, on best nursing practices for metastatic prostate cancer, from Clinical Care Options (CCO)

person default Brenda Martone, MSN, ANP-BC, AOCNP Registered Nurses: 0.75 Nursing contact hours Released: November 3, 2022 Expired: November 2, 2023

Downloadable slides from oncology nurse experts on nursing considerations for metastatic prostate cancer, from Clinical Care Options (CCO)

person default Kathleen Burns, MSN, AGACNP-BC, OCN
Program Director
person default Brenda Martone, MSN, ANP-BC, AOCNP
Program Director
Released: October 19, 2022

Slides for urologists on single-agent and combination PARP inhibitor therapy for metastatic prostate cancer, from Clinical Care Options (CCO)

Rana R. McKay, MD Released: October 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings